Rakuten Medical’s light-activatable IR700 dye is a clinically validated component used in the approved medicine Akalux™ With hydrophilicity and low toxicity1, IR700Rakuten Medical’s light-activatable IR700 dye is a clinically validated component used in the approved medicine Akalux™ With hydrophilicity and low toxicity1, IR700

Rakuten Medical Expands Academic Access to IR700 Dye Through Fee-Only Provision, Greater Publication Freedom and Expanded IP & Commercialization Opportunities

  • Rakuten Medical’s light-activatable IR700 dye is a clinically validated component used in the approved medicine Akalux™
  • With hydrophilicity and low toxicity1, IR700 dye is adaptable to diverse therapeutic modalities
  • Broader academic access to IR700 dye will accelerate open innovation and drive new medical discoveries

SAN DIEGO, Jan. 20, 2026 /PRNewswire/ — Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox® platform-based photoimmunotherapy, today announced that it will provide IRDye® 700DX N-hydroxy succinimide (NHS) ester (IR700 dye), at an administrative fee-only acquisition cost for academic research with increased flexibility for publication, intellectual property (IP) and commercialization opportunities.

IR700 dye is a pivotal component of Rakuten Medical’s proprietary Alluminox platform, which is protected by IP covering manufacturing technologies, clinical applications and I700 dye-conjugate compositions. Rakuten Medical manufactures and supplies IR700 dye worldwide, ensuring reliable quality and consistent availability.

The quality and safety of Rakuten Medical’s IR700 dye to date have been demonstrated to be acceptable within risk–benefit considerations through its use in multiple pre-clinical and clinical programs involving the company’s investigational and commercial drug assets. Among these is Akalux™ IV Infusion 250 mg, which is approved in Japan for unresectable locally advanced or recurrent head and neck cancer. Photoimmunotherapy with Akalux has been provided more than 1,200 times under Japan’s national health insurance coverage (as of January 19, 2026).

Disclaimer: Rakuten Medical’s Alluminox platform-based photoimmunotherapy is investigational outside Japan.

Through this initiative, Rakuten Medical will:

  • Provide IR700 dye for academic research under an administrative fee-only model (Material Transfer Agreement required)
  • Enable academic researchers to freely publish their findings with prior notification
  • Offer favorable conditions for IP rights arising from research outcomes
  • Expand commercialization opportunities for new innovations

Mickey Mikitani, Chief Executive Officer of Rakuten Medical, commented, “IR700 dye is a high-potential asset with applications beyond photoimmunotherapy, spanning a wide range of therapeutic modalities. By expanding academic access under more flexible terms for research, publication and innovation, we aim to accelerate the development of new treatment technologies and contribute meaningfully to advances in global healthcare.”

For inquiries regarding IR700 provision for academic research purposes, please visit:
https://rakuten-med.com/us/contact/bd/

About IRDye® 700DX N-hydroxy succinimide (NHS) ester (IR700 dye)
IR700 dye, a modified phthalocyanine, is distinguished by its hydrophilic structure, low toxicity, and light activation properties at a wavelength of 690 nm1. Since light at approximately 690 nm can penetrate tissues to a certain depth, IR700 dye is suitable for various light-based therapies, including photoimmunotherapy. Its applications range from basic research in academia to use in clinical trials. However, the complex and sensitive nature of the dye requires strict control over its synthesis, mass production, conjugation, and rigorous quality assurance processes. Rakuten Medical has developed proprietary manufacturing capabilities to ensure a stable commercial supply.

1.

Mitsunaga, Makoto et al. “Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules.” Nature medicine vol. 17,12 1685-91. 6 Nov. 2011, doi:10.1038/nm.2554

About Rakuten Medical, Inc.
Rakuten Medical, Inc. is a global biotechnology company developing and commercializing Alluminox® platform-based photoimmunotherapy, which, in pre-clinical studies, has been shown to induce rapid and selective cell killing. Rakuten Medical’s photoimmunotherapy is currently investigational outside Japan. Rakuten Medical is committed to its mission to conquer cancer by developing its pioneering treatments as quickly as possible to as many patients as possible all over the world. The company has offices in 5 countries/regions, including the United States, where it is headquartered, Japan, Taiwan, Switzerland and India. For more information, visit www.rakuten-med.com.

About Alluminox® platform 
The Alluminox® platform is Rakuten Medical’s investigational technology platform that combines pharmaceuticals, medical devices, medical technology, and other peripheral technologies. Rakuten Medical is developing Alluminox platform-based photoimmunotherapy, which involves two key steps: 1) drug administration and 2) targeted illumination using medical devices. The drug component consists of a cell-targeting moiety conjugated to a light-activatable dye, such as IRDye® 700DX (IR700), that selectively binds to the surface of targeted cells, such as tumor cells. The device component consists of a light source that locally illuminates the targeted cells with red light (690nm) to transiently activate the drug. Rakuten Medical’s pre-clinical data have shown that this activation elicits rapid and selective necrosis of targeted cells through a biophysical process that compromises the membrane integrity of the targeted cells. Therapies developed on the Alluminox platform may also result in local and systemic innate and adaptive immune activation due to immunogenic cell death of the targeted tumor cells and/or the removal of targeted immunosuppressive cells within the tumor microenvironment. Photoimmunotherapy was originally developed by Dr. Hisataka Kobayashi and his team at the National Cancer Institute in the United States. Outside Japan, Rakuten Medical’s Alluminox platform-based photoimmunotherapy is investigational.

Forward Looking Statements 
This press release contains forward looking statements that correspond to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include various risks, uncertainties, and assumptions that may cause Rakuten Medical’s business plans and results to differ from the anticipated results and expectations expressed in these statements. These “forward looking statements” contain information about the status and development of our products, including the Alluminox® platform, as well as other regulatory and marketing authorization efforts, the potential benefits, efficacy, and safety of therapies created using the Alluminox platform, and the status of regulatory filings. The approval and commercial success of the product may not be achieved. Forward looking statements relate to the potential benefits, efficacy, and safety of our therapies, and the status of regulatory filings. Such statements may include words such as “expect,” “believe,” “hope,” “estimate,” “looks as though,” “anticipate,” “intend,” “may,” “suggest,” “plan,” “strategy,” “will,” and “do”, and are based on our current beliefs. In addition, this press release uses terms such as “important,” “notable,” and “abnormal” to express opinions about clinical trial data. Ongoing clinical trial studies include various risks and uncertainties, in particular, problems that arise during the manufacturing stage of our therapies, the occurrence of adverse safety events, situations in failure to demonstrate therapeutic benefits, and other various risks and uncertainties, both reasonable and unreasonable. For this reason, actual results, including regulatory approvals and uncertainties in the commercialization process of our therapies, may differ from published information. Except to the extent required by applicable law, we undertake no obligation to publicly update this or any other forward-looking statement, whether because of new information, future developments or events, changes in assumptions, changes in the factors affecting forward-looking statements. If one or more forward-looking statement(s) is updated, no inference should be drawn that additional updates will be made to those or other forward-looking statements.

Contact Us

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/rakuten-medical-expands-academic-access-to-ir700-dye-through-fee-only-provision-greater-publication-freedom-and-expanded-ip–commercialization-opportunities-302665130.html

SOURCE Rakuten Medical, Inc.

Market Opportunity
Story Logo
Story Price(IP)
$1.798
$1.798$1.798
-7.93%
USD
Story (IP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

21Shares Launches JitoSOL Staking ETP on Euronext for European Investors

21Shares Launches JitoSOL Staking ETP on Euronext for European Investors

21Shares launches JitoSOL staking ETP on Euronext, offering European investors regulated access to Solana staking rewards with additional yield opportunities.Read
Share
Coinstats2026/01/30 12:53
Digital Asset Infrastructure Firm Talos Raises $45M, Valuation Hits $1.5 Billion

Digital Asset Infrastructure Firm Talos Raises $45M, Valuation Hits $1.5 Billion

Robinhood, Sony and trading firms back Series B extension as institutional crypto trading platform expands into traditional asset tokenization
Share
Blockhead2026/01/30 13:30
Summarize Any Stock’s Earnings Call in Seconds Using FMP API

Summarize Any Stock’s Earnings Call in Seconds Using FMP API

Turn lengthy earnings call transcripts into one-page insights using the Financial Modeling Prep APIPhoto by Bich Tran Earnings calls are packed with insights. They tell you how a company performed, what management expects in the future, and what analysts are worried about. The challenge is that these transcripts often stretch across dozens of pages, making it tough to separate the key takeaways from the noise. With the right tools, you don’t need to spend hours reading every line. By combining the Financial Modeling Prep (FMP) API with Groq’s lightning-fast LLMs, you can transform any earnings call into a concise summary in seconds. The FMP API provides reliable access to complete transcripts, while Groq handles the heavy lifting of distilling them into clear, actionable highlights. In this article, we’ll build a Python workflow that brings these two together. You’ll see how to fetch transcripts for any stock, prepare the text, and instantly generate a one-page summary. Whether you’re tracking Apple, NVIDIA, or your favorite growth stock, the process works the same — fast, accurate, and ready whenever you are. Fetching Earnings Transcripts with FMP API The first step is to pull the raw transcript data. FMP makes this simple with dedicated endpoints for earnings calls. If you want the latest transcripts across the market, you can use the stable endpoint /stable/earning-call-transcript-latest. For a specific stock, the v3 endpoint lets you request transcripts by symbol, quarter, and year using the pattern: https://financialmodelingprep.com/api/v3/earning_call_transcript/{symbol}?quarter={q}&year={y}&apikey=YOUR_API_KEY here’s how you can fetch NVIDIA’s transcript for a given quarter: import requestsAPI_KEY = "your_api_key"symbol = "NVDA"quarter = 2year = 2024url = f"https://financialmodelingprep.com/api/v3/earning_call_transcript/{symbol}?quarter={quarter}&year={year}&apikey={API_KEY}"response = requests.get(url)data = response.json()# Inspect the keysprint(data.keys())# Access transcript contentif "content" in data[0]: transcript_text = data[0]["content"] print(transcript_text[:500]) # preview first 500 characters The response typically includes details like the company symbol, quarter, year, and the full transcript text. If you aren’t sure which quarter to query, the “latest transcripts” endpoint is the quickest way to always stay up to date. Cleaning and Preparing Transcript Data Raw transcripts from the API often include long paragraphs, speaker tags, and formatting artifacts. Before sending them to an LLM, it helps to organize the text into a cleaner structure. Most transcripts follow a pattern: prepared remarks from executives first, followed by a Q&A session with analysts. Separating these sections gives better control when prompting the model. In Python, you can parse the transcript and strip out unnecessary characters. A simple way is to split by markers such as “Operator” or “Question-and-Answer.” Once separated, you can create two blocks — Prepared Remarks and Q&A — that will later be summarized independently. This ensures the model handles each section within context and avoids missing important details. Here’s a small example of how you might start preparing the data: import re# Example: using the transcript_text we fetched earliertext = transcript_text# Remove extra spaces and line breaksclean_text = re.sub(r'\s+', ' ', text).strip()# Split sections (this is a heuristic; real-world transcripts vary slightly)if "Question-and-Answer" in clean_text: prepared, qna = clean_text.split("Question-and-Answer", 1)else: prepared, qna = clean_text, ""print("Prepared Remarks Preview:\n", prepared[:500])print("\nQ&A Preview:\n", qna[:500]) With the transcript cleaned and divided, you’re ready to feed it into Groq’s LLM. Chunking may be necessary if the text is very long. A good approach is to break it into segments of a few thousand tokens, summarize each part, and then merge the summaries in a final pass. Summarizing with Groq LLM Now that the transcript is clean and split into Prepared Remarks and Q&A, we’ll use Groq to generate a crisp one-pager. The idea is simple: summarize each section separately (for focus and accuracy), then synthesize a final brief. Prompt design (concise and factual) Use a short, repeatable template that pushes for neutral, investor-ready language: You are an equity research analyst. Summarize the following earnings call sectionfor {symbol} ({quarter} {year}). Be factual and concise.Return:1) TL;DR (3–5 bullets)2) Results vs. guidance (what improved/worsened)3) Forward outlook (specific statements)4) Risks / watch-outs5) Q&A takeaways (if present)Text:<<<{section_text}>>> Python: calling Groq and getting a clean summary Groq provides an OpenAI-compatible API. Set your GROQ_API_KEY and pick a fast, high-quality model (e.g., a Llama-3.1 70B variant). We’ll write a helper to summarize any text block, then run it for both sections and merge. import osimport textwrapimport requestsGROQ_API_KEY = os.environ.get("GROQ_API_KEY") or "your_groq_api_key"GROQ_BASE_URL = "https://api.groq.com/openai/v1" # OpenAI-compatibleMODEL = "llama-3.1-70b" # choose your preferred Groq modeldef call_groq(prompt, temperature=0.2, max_tokens=1200): url = f"{GROQ_BASE_URL}/chat/completions" headers = { "Authorization": f"Bearer {GROQ_API_KEY}", "Content-Type": "application/json", } payload = { "model": MODEL, "messages": [ {"role": "system", "content": "You are a precise, neutral equity research analyst."}, {"role": "user", "content": prompt}, ], "temperature": temperature, "max_tokens": max_tokens, } r = requests.post(url, headers=headers, json=payload, timeout=60) r.raise_for_status() return r.json()["choices"][0]["message"]["content"].strip()def build_prompt(section_text, symbol, quarter, year): template = """ You are an equity research analyst. Summarize the following earnings call section for {symbol} ({quarter} {year}). Be factual and concise. Return: 1) TL;DR (3–5 bullets) 2) Results vs. guidance (what improved/worsened) 3) Forward outlook (specific statements) 4) Risks / watch-outs 5) Q&A takeaways (if present) Text: <<< {section_text} >>> """ return textwrap.dedent(template).format( symbol=symbol, quarter=quarter, year=year, section_text=section_text )def summarize_section(section_text, symbol="NVDA", quarter="Q2", year="2024"): if not section_text or section_text.strip() == "": return "(No content found for this section.)" prompt = build_prompt(section_text, symbol, quarter, year) return call_groq(prompt)# Example usage with the cleaned splits from Section 3prepared_summary = summarize_section(prepared, symbol="NVDA", quarter="Q2", year="2024")qna_summary = summarize_section(qna, symbol="NVDA", quarter="Q2", year="2024")final_one_pager = f"""# {symbol} Earnings One-Pager — {quarter} {year}## Prepared Remarks — Key Points{prepared_summary}## Q&A Highlights{qna_summary}""".strip()print(final_one_pager[:1200]) # preview Tips that keep quality high: Keep temperature low (≈0.2) for factual tone. If a section is extremely long, chunk at ~5–8k tokens, summarize each chunk with the same prompt, then ask the model to merge chunk summaries into one section summary before producing the final one-pager. If you also fetched headline numbers (EPS/revenue, guidance) earlier, prepend them to the prompt as brief context to help the model anchor on the right outcomes. Building the End-to-End Pipeline At this point, we have all the building blocks: the FMP API to fetch transcripts, a cleaning step to structure the data, and Groq LLM to generate concise summaries. The final step is to connect everything into a single workflow that can take any ticker and return a one-page earnings call summary. The flow looks like this: Input a stock ticker (for example, NVDA). Use FMP to fetch the latest transcript. Clean and split the text into Prepared Remarks and Q&A. Send each section to Groq for summarization. Merge the outputs into a neatly formatted earnings one-pager. Here’s how it comes together in Python: def summarize_earnings_call(symbol, quarter, year, api_key, groq_key): # Step 1: Fetch transcript from FMP url = f"https://financialmodelingprep.com/api/v3/earning_call_transcript/{symbol}?quarter={quarter}&year={year}&apikey={api_key}" resp = requests.get(url) resp.raise_for_status() data = resp.json() if not data or "content" not in data[0]: return f"No transcript found for {symbol} {quarter} {year}" text = data[0]["content"] # Step 2: Clean and split clean_text = re.sub(r'\s+', ' ', text).strip() if "Question-and-Answer" in clean_text: prepared, qna = clean_text.split("Question-and-Answer", 1) else: prepared, qna = clean_text, "" # Step 3: Summarize with Groq prepared_summary = summarize_section(prepared, symbol, quarter, year) qna_summary = summarize_section(qna, symbol, quarter, year) # Step 4: Merge into final one-pager return f"""# {symbol} Earnings One-Pager — {quarter} {year}## Prepared Remarks{prepared_summary}## Q&A Highlights{qna_summary}""".strip()# Example runprint(summarize_earnings_call("NVDA", 2, 2024, API_KEY, GROQ_API_KEY)) With this setup, generating a summary becomes as simple as calling one function with a ticker and date. You can run it inside a notebook, integrate it into a research workflow, or even schedule it to trigger after each new earnings release. Free Stock Market API and Financial Statements API... Conclusion Earnings calls no longer need to feel overwhelming. With the Financial Modeling Prep API, you can instantly access any company’s transcript, and with Groq LLM, you can turn that raw text into a sharp, actionable summary in seconds. This pipeline saves hours of reading and ensures you never miss the key results, guidance, or risks hidden in lengthy remarks. Whether you track tech giants like NVIDIA or smaller growth stocks, the process is the same — fast, reliable, and powered by the flexibility of FMP’s data. Summarize Any Stock’s Earnings Call in Seconds Using FMP API was originally published in Coinmonks on Medium, where people are continuing the conversation by highlighting and responding to this story
Share
Medium2025/09/18 14:40